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Genome-wide association studies have identified a region on chromosome 9p that is associated with coronary
artery disease (CAD). The region is also associated with type 2 diabetes (T2D), a risk factor for CAD, although
different SNPswere reported to be associated to eachdisease in separate studies.Wehave undertaken a case–
control study in 4251CADcases and 4443 controls in four European populationsusing previously reported (‘lit-
erature’) and tagging SNPs.We replicated the literature SNPs (P 5 8310213; OR 5 1.29; 95%CI: 1.20–1.38) and
showed that the strong consistent association detected by these SNPs is a consequence of a ‘yin-yang’ haplo-
type pattern spanning 53 kb. There was no evidence of additional CAD susceptibility alleles over the major risk
haplotype. CAD patients without myocardial infarction (MI) showed a trend towards stronger association than
MI patients. The CAD susceptibility conferred by this locus did not differ by sex, age, smoking, obesity, hyper-
tensionordiabetes.Asimultaneous test ofCADanddiabetes susceptibilitywithCADandT2D-associatedSNPs
indicated that these associations were independent of each other. Moreover, this region was not associated
with differences in plasma levels of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol,
fibrinogen, albumin, uric acid, bilirubin or homocysteine, although the CAD-high-risk allele was paradoxically
associated with lower triglyceride levels. A large antisense non-coding RNA gene (ANRIL) collocates with the
high-risk haplotype, is expressed in tissues and cell types that are affected by atherosclerosis and is a prime
candidate gene for the chromosome 9p CAD locus.
INTRODUCTION
Coronary artery disease (CAD) is the commonest cause of
death worldwide and has a rapidly increasing incidence in
nations undergoing industrial development (1). CAD is a mul-
tifactorial disease in which multiple genes and environmental
factors are believed to influence disease risk. Candidate gene,
positional cloning and comparative mapping techniques have
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identified a number of susceptibility genes for CAD, but the
identity of the genes explaining much of the heritability of
CAD remains unknown (1).
Recent genome-wide association (GWA) studies have
tested the common disease/common variant (CD/CV) hypoth-
esis and successfully identified susceptibility genes for a
number of multifactorial diseases including CAD. The most
striking CAD result involves a genomic region on chromo-
some 9 approximately 22 million base pairs from the 9p
telomere (2–5). Single nucleotide polymorphisms (SNPs)
showing the strongest association with CAD did not map
within an annotated gene sequence leading to the nomination
of neighbouring genes (CDKN2A, CDNK2B and MTAP) as
candidate susceptibility genes.
Contemporaneous GWA studies of type 2 diabetes (T2D)
susceptibility identified the same region on chromosome 9 in
several (6–8) but not all (9,10) populations. Diabetes mellitus
(DM) has long been recognized as a major risk factor for
atherosclerosis with a complex pathogenesis involving mul-
tiple biological processes. For instance, increased reactive
oxidant stress in diabetic arterial walls contributes to endo-
thelial damage, the earliest stage in the development of an
atherosclerotic plaque. Subsequently, features of the insulin
resistance syndrome associated with T2D such as hyperlipi-
daemia and hypertension exacerbate the damage and lead to
disease progression. The temporal relationship of DM with
CAD is complex; DM may precede the onset of CAD symp-
toms, or be diagnosed de novo as a consequence of a CAD
clinical presentation or appear shortly after a major CAD
event such as myocardial infarction (MI) (11,12). Conse-
quently, the co-localization of CAD and T2D susceptibility
genes would seem, at first glance, as likely to point to a
tightly coupled pathophysiological mechanism. However, the
reports of CAD and T2D susceptibility (in non-overlapping
patient populations) apparently involve different genetic
markers. Moreover, quantitative genetic analysis of intermedi-
ate phenotypes associated with the pro-atherogenic insulin
resistance phenotype detected no obvious QTL effects with
CAD-associated SNPs. These intriguing findings motivate
studies that aim to disentangle the susceptibility effects
encoded by this chromosome 9p CAD/T2D susceptibility
locus.
The PROCARDIS consortium was conceived to study the
complex genetics of CAD susceptibility in Europeans and
has assembled clinical resources to undertake genetic associ-
ation studies. We have undertaken a genetic analysis of
markers spanning the chromosome 9p susceptibility region
in 4251 cases and 4443 controls to replicate the CAD locus,
interpret the pattern of association in the context of European
haplotype diversity and investigate if established risk factors
(in particular diabetes) modify the CAD susceptibility effect.
RESULTS
SNP selection
SNPs were selected on the basis of earlier reports of associa-
tion to CAD or to tag additional genetic variation based on the
HapMap CEU (CEPH European ancestry) database. First, the
chromosome 9p region was partitioned into several sections
spanning 403.8 kb (21 790 000–22 193 800 bp): a 68 kb core
section containing SNPs reported to show strong association
with CAD and T2D (22 057 000–22 125 000 bp); a broader
185 kb region containing SNPs showing moderate association
to CAD (21 940 000–22 125 000); two sections incorporating
adjacent linkage disequilibrium (LD) blocks (150 kb upstream
and 68.8 kb downstream). All published associated SNPs were
selected for genotyping (Table 1) except for two where an
alternative in strong LD (r2  0.9) was used instead
(rs10811650 was replaced by rs10811647 and rs6475608
was replaced by rs4977756). HaploView (13) was used to
select additional tagging SNPs with MAF . 0.2 and r2  0.9
for the core region and r2  0.5 across the 403.8 kb region.
The list of SNPs genotyped is shown in Supplementary
Material, Table S1.
Replication of SNP associations with CAD
Table 1 shows the results of an analysis of 11 SNPs previously
reported to show strong association to CAD or T2D in single
marker tests (literature SNPs). The PROCARDIS cases (n ¼
4251) were patients with documented diagnoses of MI, symp-
tomatic acute coronary syndrome, intervention for coronary
revascularization, or chronic stable angina with an age at diag-
nosis of 65 years or less. The controls (n ¼ 4,443) were self-
reportedly free of coronary disease at age 65 and without
any sibling history of CAD. Two CAD literature SNPs
(rs518394 and rs1333040) were genotyped but showed
marked distortion of Hardy–Weinberg equilibrium in the
control group (P  .0005) and were eliminated from further
analysis. The seven remaining CAD literature SNPs showed
strong evidence of association (810213  P  310211)
with strikingly similar odds ratio estimates ranging from
1.29 to 1.26. There was no evidence of non-additivity (P 
0.36) on the logit scale consistent with an allelic-effects-only
association model. There was also no evidence of heterogen-
eity of the association across the four European populations
(P  0.86). Four T2D literature SNPs were genotyped and
passed the QC criteria, one SNP (rs564398) showed significant
(P ¼ 41028) association to CAD with no evidence of het-
erogeneity (P ¼ 0.27) across the countries. SNP rs564398
was in moderate LD with the 7 CAD literature SNPs
(0.29  r2  0.41).
Identification of a parsimonious SNP association model
A further 21 tagging SNPs were genotyped in the complete
PROCARDIS panel of 4251 cases and 4443 controls. These
SNPs were combined with the literature SNPs described
above to form a model selection data set; the overall genotype
call-rate across the 32 SNPs was 98.8%. However, 19% of the
genotypes were incomplete for one SNP and 7% for between
two and five SNPs. The strong LD between some of the SNPs
(details shown below) motivated a combined haplotyping/gen-
otype imputation analysis to infer missing genotypes using
information from flanking markers. Following haplotype and
genotype imputation with the MACH program using a
quality score threshold of 0.85, the proportion of incomplete
genotypes was halved to 13% so overall, 99.5% of genotypes
were available for analysis.
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A forward stepwise model selection procedure was applied
to identify a subset of SNPs with strong main-effects associ-
ation to CAD. In this conditional association analysis, model-
ling additive (logit scale) genetic effects, a single SNP,
rs2891168 was identified in the combined-countries data
using an entry P-value threshold of 0.01. Association
between CAD and rs2891168 was strongly supported (P ¼
610213) and the per-G-allele odds ratio ¼ 1.29 (95% CI
1.20–1.38). There was no evidence for non-additive (logit
scale) susceptibility effects (P ¼ 0.69); there was also no evi-
dence of heterogeneity of susceptibility across the four Euro-
pean populations (Cochrane’s Q ¼ 0.37, 3 d.f., P ¼ 0.95)
(Fig. 1).
In order to extend the search for SNPs that complement the
susceptibility defined by rs2891168, 32 additional tagging/
fine-mapping SNPs were genotyped in a subset of the PRO-
CARDIS cases (n ¼ 1699) and controls (n ¼ 1896). One of
these SNPs, rs12379111, was excluded from further analysis
on the basis of a low (72%) genotype call-rate. A combined
haplotype and genotype imputation analysis was again used
to maximize the genetic information as 26% of genotypes
were incomplete for 1–5 SNPs; this was reduced to 9%
after imputation. A forward stepwise model selection pro-
cedure was then applied with rs2891168 forcibly included as
an additive-effect in the model. This analysis failed to identify
any further associated SNPs with significant main-effects
(P. 0.01).
Common haplotypes delimit CAD susceptibility
Supplementary Material, Figure S1 shows a representation of
the pairwise LD coefficients (scaled as r2) for 62 SNPs span-
ning the chromosome 9p CAD locus based on a combined
(cases and controls) data set. There is a region of strong LD
with flanking SNPs rs10116277 (22 071 397 bp) and
rs1333049 (22 115 503 bp) in which 13 SNPs show r2 
0.77 with rs2891168. Haplotype analysis (Table 2) shows
that these 14 SNPs form four common haplotypes (cumulative
frequency ¼ 89%) in which a perfect complementary yin–
yang pattern is maintained (14). All seven CAD literature
SNPs reported in Table 1 comply with the yin–yang pattern.
An analysis of this region in the CEPH European HapMap
data shows that this striking LD pattern is maintained across
37 SNPs from rs10757269 (22 062 264 bp) to rs1333049
(22 115 503 bp) (Supplementary Material, Table S2). There
is also no evidence of long range LD on chromosome 9 with
an r2  0.5 criterion (Dr Robert Lawrence, WTCHG, personal
communication).
Susceptibility in disease and risk factor subgroups
A multinomial logistic regression model was used to test if
susceptibility to CAD detected by rs2891168 might vary in
CAD patients with different clinical diagnostic or risk factor
profiles (Fig. 2). CAD patients (n ¼ 1361) with no clinical
history of MI showed a trend towards stronger association
than CAD patients who had suffered MI (n ¼ 2890) (OR ¼
1.36 versus 1.26; x2 ¼ 3.1, 1 d.f.; P ¼ 0.08). There were no
Figure 1. CAD association with rs2891168 in four European populations.
Horizontal lines indicate 95% confidence intervals (CI) for odds ratio (OR)
estimates in each country. The overall (fixed-effects) estimate of the OR is
shown by a vertical dashed line, the 95% CI for this estimate is shown by
an unshaded rhombus. Solid squares are centered on the OR estimate for
each country and scaled in proportion to the number of participants in each
country (number of cases and controls shown in parentheses).
Table 1. Association analysis of CAD with literature SNPs
SNP Position
(bp)
HWE
x2
Risk
allele
freq. OR 95% CI Additive effects
2log10(P-value)
Non-additive
effects P-value
het.
P-value
Selection
criterion of
reported
association
Publication
rs564398 22 019 547 7.0 T 0.58 1.21 1.13–1.30 7.4 0.07 0.27 T2D Scott&Zeggini
rs10116277 22 071 397 0.5 T 0.48 1.28 1.19–1.37 11.6 0.36 0.94 CAD Helgadottir
rs6475606 22 071 850 0.4 T 0.48 1.27 1.19–1.36 11.5 0.41 0.93 CAD McPherson&WTCCC
rs10757274 22 086 055 0.3 G 0.48 1.29 1.20–1.38 12.1 0.69 0.86 CAD McPherson
rs2383206 22 105 026 0.2 G 0.51 1.26 1.18–1.35 10.5 0.50 0.97 CAD McPherson
rs2383207 22 105 959 0.0 G 0.51 1.27 1.18–1.36 10.8 0.37 0.97 CAD Helgadottir
rs10757278 22 114 477 1.2 G 0.47 1.27 1.19–1.37 11.3 0.62 0.89 CAD Helgadottir
rs1333049 22 115 503 1.1 C 0.48 1.27 1.19–1.36 11.1 0.72 0.86 CAD McPherson&WTCCC
rs2383208 22 122 076 0.4 G 0.20 1.02 0.93–1.11 0.2 0.51 0.43 T2D Scott
rs10811661 22 124 094 1.0 T 0.82 1.02 0.93–1.11 0.2 0.62 0.59 T2D Scott&Zeggini
rs10757283 22 124 172 0.0 T 0.43 1.07 1.00–1.15 1.3 0.67 0.73 T2D Zeggini
HWE x2, Hardy–Weinberg equilibrium x2 statistic; freq., frequency of risk allele; het. P-value, fixed-effects heterogeneity test P-value.
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significant differences in CAD susceptibility detected by
rs2891168 contrasting those who had regularly smoked with
those who had never regularly smoked (P ¼ 0.98), male
versus female CAD patients (P ¼ 0.14), CAD patients with
age-of-onset earlier or later than age 55 (P ¼ 0.34), with
BMI greater or less than 30 kg/m2 (P ¼ 0.53), self-reported
history of diabetes (P ¼ 0.82) or hypertension (P ¼ 0.47).
A further multinomial logistic regression model was fitted
to simultaneously assess association between CAD and
rs2891168 and diabetes status and rs10811661 (Fig. 3). SNP
rs10811661 was selected as it showed the strongest and
most consistent association in a meta-analysis of T2D GWA
studies (8) and maps outside of the CAD-associated haplotype
(Fig. 4). CAD and diabetes status are strongly positively
correlated (tetrachoric correlation ¼ 0.45+ 0.02) in the
PROCARDIS populations and rs2891168 and rs10811661
are in LD (r2 ¼ 0.008). Using a reference group of
non-CAD/non-diabetics, the rs10811661/CAD/diabetics logit
was significantly (P ¼ 0.016) higher than the rs10811661/
CAD/non-diabetics logit consistent with the reported associ-
ation of the T-allele with T2D risk. A nested model with
linear constraints designed to specify marginal
rs2891168-CAD and rs10811661-diabetes effects only,
was not rejected in a likelihood ratio test (x2 ¼ 1.8, 4 d.f.,
P ¼ 0.77). Thus the two SNPs are independently associated
with the two separate diseases in the PROCARDIS population.
Biochemical intermediate phenotypes measured in CAD
cases were tested for QTL effects with rs2891168 (Table 3).
There was no evidence of association to plasma levels of
low-density lipoprotein (LDL)-cholesterol, high-densityT
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Figure 2. Association between CAD and rs2891168 in clinical and risk factor
subgroups. Solid squares centered on the OR estimate and scaled in proportion
to sample size with 95% CI (horizontal bar) are shown for subgroups contrast-
ing CAD with or without a history of MI, history of regular smoking, sex,
age at first clinical presentation, obesity, clinical history of diabetes or
hypertension.
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lipoprotein (HDL) cholesterol, lipoprotein(a), albumin, fibri-
nogen, uric acid or homocysteine (all P. 0.11). There was
evidence of association with triglyceride levels (P ¼ 0.009);
the high-CAD risk G-allele was associated with lower levels
of this lipid.
ANRIL is expressed in cells and tissues affected
by atherosclerosis
Primers were designed to PCR amplify exons 17, 18 and 19 of
the 30-UTR of the reported ANRIL transcript DQ485453 (15).
These exons fall within the CAD-associated haplotype (Fig. 4)
and are represented by three ESTs (BX100299, A1825844,
AW169296). Total RNA was extracted, and amplified by
RT–PCR, from human cells and tissues of potential relevance
to CAD: human umbilical vein endothelial (HUVEC) and
human microvascular endothelial (HMEC) cell lines;
HepG2, Jurkat and THP1 cell lines; primary coronary
smooth muscle and human monocyte-derived macrophage
cell cultures and carotid endarterectomy (CEA) and abdominal
aortic aneurysm (AAA) samples. Expression was shown in the
CEA and AAA tissue samples, and also the HUVEC and
HMEC endothelial cells, macrophages, HepG2 and coronary
smooth muscle cells but not the Jurkat and THP1 cell lines
(Fig. 5).
DISCUSSION
It is encouraging to report that the associations between SNPs
on chromosome 9p and CAD risk are convincingly and inde-
pendently confirmed in the PROCARDIS samples (Table 1).
Replication of candidate gene associations can prove very dif-
ficult (16) and consistent susceptibility effects are needed to
provide a firm rationale for further biological experimentation.
The magnitude of the susceptibility effect in the four European
populations (OR ¼ 1.29) is very similar to that reported in the
GWA studies. The absolute magnitude of the susceptibility
effect is modest in comparison to classic risk factors (e.g.
smoking, OR . 3) noting that this locus conferred the
largest effect detected in three GWA studies to date.
The results of the different GWA studies that identified the
chromosome 9p CAD locus included partially overlapping sets
of associated SNPs. We show here that the strongest associ-
ations are coupled to a pair of high and low risk haplotypes
that constitute a yin–yang pattern (Table 2 and Fig. 4) (14).
An analysis of the HapMap database suggests that this haplo-
type pattern is extended across a region of at least 53 kb.
Given the apparent low frequency of minor haplotypes that
would be informative for further fine-mapping, the prospects
for further resolving the susceptibility within CAD popu-
lations of European ancestry are limited. Indeed even
large-scale re-sequencing is unlikely to contribute much.
Using models of conditional association, we sought evidence
for secondary risk alleles in moderate or low LD with the
major susceptibility region. This was unsuccessful using a
P-entry criterion of 0.01. We applied a forward stepwise pro-
cedure which implements a ‘greedy’ algorithm that is prone to
Figure 4. The chromosome 9p CAD region. The upper panel shows odds ratio
(OR) estimates in red plotted against physical location (bp) for 62 SNPs tested
in the PROCARDIS case–control study. The exon–intron structure of anno-
tated genes are shown in blue; the location of the CAD-associated haplotype
is shown in green; the location of the T2D-associated SNP (rs10811661) is
shown in purple. The lower panel summarizes the linkage disequilibrium
(LD) structure in the HapMap database (CEU European ancestry). Regions
of LD are shaded in grey (moderate LD) or black (strong LD). Predicted hap-
lotype blocks are framed by triangles. The physical location of the HapMap
SNPs is shown above the haplotype blocks.
Figure 3. Association to CAD and diabetes with rs2891168 and rs10811661.
Solid squares centered on the relative risk ratio estimate and scaled in pro-
portion to sample size with 95% CI (horizontal bar) for subgroups contrasting
CAD with or without a clinical history of diabetes. The reference group is
non-CAD, non-diabetics (n ¼ 4305). The number of individuals in each
subgroup (n) is shown.
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overestimate the magnitude of regression parameters of pre-
dictors included in a model, with the consequence that second-
ary predictors might be overlooked (i.e. type II error).
However, relaxing the P-entry criterion could easily lead to
over-fitting (type I error), a serious possibility as 62 SNPs
were available for testing. We therefore interpret our results
to show that at least the great majority of the CAD suscepti-
bility is encoded by two common haplotypes spanning a
53 kb region and that any linked minor variants will be associ-
ated with relatively small effects.
The CAD association appears remarkably uniform with no
evidence of gene–environmental interactions in that it does
not appear to be modified by age, sex, smoking history,
obesity or presence of hypertension or diabetes. The suscepti-
bility effect in CAD cases with no clinical history of MI
showed a trend towards stronger association compared with
those who had survived an infarct. This result would seem
to exclude the chromosome 9p CAD locus as a ‘plaque
rupture’, or thrombosis, gene. On the other hand,
genes acting at a very early stage in the development of an
atheromatous plaque might be predicted to show similar
risks in CAD patients with or without MI. So speculatively,
this locus might promote the development of stable, obstruc-
tive, plaques and it will be interesting to see if the subtle
trend reported here is confirmed in other collections of CAD
patients.
The reports of T2D susceptibility detected by different
SNPs to those reported in CAD studies were tested in a multi-
nomial logit model in which a CAD associated SNP
(rs2891168) and a T2D associated SNP (rs10811661) were
simultaneously fitted to a joint CAD/diabetes outcome. The
results of this analysis are consistent with the hypothesis that
the two susceptibility effects are independent; this is the first
time this has been formally tested. A limitation of the
present study was the inability to distinguish sub-types of dia-
betes, but the proportion of diabetes in the PROCARDIS
population attributable to T2D is likely to exceed 90% based
on prevalence data and the age-range of the population. Fur-
thermore, although there are a considerable number of infor-
mative patients with CAD and diabetes in the PROCARDIS
collection, the numbers of non-CAD diabetics are relatively
low which inevitably limits the power of this study to reject
the null hypothesis of independence. Case–control collections
designed to assess association of susceptibility genes with
CAD such as PROCARDIS are typically based on the
disease criterion of primary interest to the investigators; it
would be very difficult to ascertain and assemble large
numbers of CAD cases and controls in a balanced design
across (potentially multiple) risk factor subgroups. Progress
therefore may be dependent on large-scale prospective
studies such as UK Biobank (www.ukbiobank.ac.uk) which
have the potential to provide nested-case–control samples
(for example CAD cases and controls with or without T2D
or other risk factors) to test such hypotheses.
There was no evidence of an influence of the CAD risk hap-
lotype on quantitative variation for LDL-cholesterol or HDL-
cholesterol levels, lipoprotein(a), fibrinogen or albumin,
homocysteine or bilirubin in PROCARDIS cases. Conse-
quently, this genetic susceptibility to CAD appears not to be
mediated by influences on known pathogenic mechanisms
such as altered lipid metabolism or inflammation. There was
some evidence of a QTL effect for triglyceride levels noting
that the CAD high-risk allele was associated with lower
Table 3. QTL analysis of biochemical risk factors for CAD
Phenotype Transformation or variance adjustment rs2891168 (per G allele effect) Covariates included in model
coefficient S.E. F d.f. P-value
LDL-C Log 21.71022 2.61022 0.4 750 5.11021 Sex
HDL-C Log 3.31022 2.11022 2.5 748 1.11021 Sex, age, BMI
TG Log 21.01021 3.91022 6.9 749 9.11023 BMI
Lp(a) Log 23.51023 5.41022 0.0 751 9.51021 Sex
Albumin Bootstrap 1.7101 1.9101 0.9 752 3.51021 Sex, age
Fibrinogen Bootstrap 1.31022 2.31022 0.3 1817 5.81021 Sex, age, BMI, current smoking, cotinine
Homocysteine 1/sqrt 23.61024 2.31023 0.0 750 8.91021 Sex, age, cotinine
Bilirubin Log 8.01023 1.31022 0.4 1830 5.31021 Sex, age, BMI, current smoking, cotinine
Urate Sqrt 5.41023 7.31023 0.6 1839 4.61021 Sex, age, BMI, current smoking
coefficient, regression coefficient scaled in transformed or original units; S.E., standard error of regression coefficients; F, F-statistic (numerator degrees
of freedom¼1); d.f., denominator degrees of freedom.
Figure 5. RT–PCR analysis of ANRIL expression. NRT, no-reverse transcrip-
tase control; NTC, no-template control; CEA, carotid endarterectomy; AAA,
abdominal aortic aneurysm; HUVEC, human umbilical vein endothelial
cells; HCSM, human coronary artery smooth muscle; Hep G2, human hepato-
cellular carcinoma cell lines; CaCo2, human colon cancer cell line; Jurkat,
immortalized T-cell line; THP1, human acute monocytic leukaemia cell
line; HMEC, human microvascular endothelial cell line.
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lipid levels. Triglyceride has been reported as an independent
risk factor for CAD and is a component of the metabolic syn-
drome; higher levels of triglyceride are associated with
increased CAD risk (17–20). Thus the risk conferred by this
locus is not easily explained by a lowering of triglyceride
levels. Further, published mapping studies have not detected
an association between triglyceride levels and chromosome
9p (2), suggesting that this result may be a false-positive
and should be regarded as tentative. In aggregate, the lack
of association between variation at this locus and known inter-
mediate phenotypes for CAD suggests that the underlying
gene(s) may operate by a novel mechanism.
Figure 4 summarizes the association results in the PRO-
CARDIS populations in the context of known genes in the
chromosome 9p region. The high-risk CAD haplotype over-
laps with exons 13–19 of ANRIL, a newly annotated gene
which encodes a large antisense non-coding RNA (ncRNA)
that was identified through a deletion analysis of an extended
French family with hereditary melanoma-neural system
tumours (15). Our RT–PCR studies show that ANRIL is
expressed in atheromatous human vessels (abdominal aortic
aneurysm and carotid endarterectomy samples), tissues with
comparable cell type profiles to atherosclerotic coronary
arteries. ANRIL was expressed in vascular endothelial cells,
monocyte-derived macrophages and coronary smooth muscle
cells, all of which are involved in atherosclerosis. As is
typical of most ncRNAs at present, very little is currently
known of the function of ANRIL, a class of gene which is
thought to add to a cell’s transcriptional control repertoire
(21). A survey of the dbSNP database revealed no SNPs that
map within exons that collocate with the risk haplotype.
However, multiple SNPs coupled to the high-risk haplotype
map to intronic or downstream sequences; these variants are
plausible candidates for influencing levels of ANRIL
expression. However, the downstream targets of ANRIL
remain to be discovered as do any interactions with neighbour-
ing genes.
To conclude, the discovery and replication of a convincing
susceptibility locus for CAD and T2D on chromosome 9p has
opened unanticipated lines of enquiry into molecular pathways
underlying these diseases. The apparent independence of var-
iants for each disease is intriguing, as is the coincidence of
high-risk haplotype for CAD and an ncRNA sequence of
unknown function. Further experiments that will stretch the
resolution of currently available techniques for studying
the complex interplay of cis- and/or trans-acting factors will
be needed to identify details of the molecular basis of the
susceptibility.
MATERIALS AND METHODS
Samples
A detailed description of the PROCARDIS population can be
found elsewhere (22). In brief CAD cases were collected using
physician-confirmed diagnoses of MI, symptomatic acute cor-
onary syndrome, chronic stable angina or intervention for cor-
onary revascularization at or before the age of 65 years.
Controls with no personal or sibling history of CAD
(at or before age 65 years) were identified through the same
recruitment infrastructure. The age-at-recruitment was
similar for cases and controls; 92.8% of the cases and 90.0%
of the controls were born between 1930 and 1960. Recruit-
ment of participants was carried out in Germany, Italy,
Sweden and the UK with an approximate 1:1 ratio of cases:
controls from each country. All participants reported having
white European ancestry. The protocol was approved by the
Ethics Committees of the participating institutions and all par-
ticipants gave written, informed consent. DNA was extracted
and quantified as previously described (22).
Multiplex genotyping
SNP genotyping was performed by primer extension and
MALDI-TOF mass spectrometry, using Sequenom iPLEXTM
technology (Sequenom Inc. San Diego. CA). Sequenom
Mass Array Design Software (v.3.0) was used to design 70
SNP assays (in two multiplex reactions, iPLEX1 and
iPLEX2) across the chromosome 9p region. PCR was per-
formed using 20 ng of DNA in a reaction volume of 10 ml con-
taining 2U of HotStar Taq (Qiagen, Valencia, CA, USA),
1 mM each dNTP and 200 nM each primer. PCR was per-
formed at 948C for 15 min followed by 45 cycles of 948C
for 20 s, 568C for 30 s and 728C for 1 min and finally 1
cycle of 728C for 3 min. 0.3 U of shrimp alkaline phosphatase
was added and the samples incubated at 378C for 20 min fol-
lowed by 858C for 5 min to inactivate the enzyme. Assays
were divided into four groups according to mass and extension
primer concentrations adjusted to reduce signal-to-noise ratio.
A 5 ml extension reaction containing 0.041 ml DNA polymer-
ase, 0.2 ml termination reaction and either 7, 9, 11 or 14 mM of
extension primer was added. Reactions were incubated at
948C for 30 s followed by 40 cycles of annealing (948C for
5 s) and extension (5 cycles of 528C 5 s and 808C 5 s),
followed by 728C for 3 min. The samples were desalted and
dispensed onto a 384 element SpectroCHIP bioarray. Mass
ARRAY Workstation version 3.3 software was used to
process and analyse the SpectroCHIP bioarrays.
Genotyping quality control
Genotype cluster plots were manually examined. Four SNPs
were eliminated from further analysis due to poor clustering
(rs1333046, rs2069422, rs7866410, rs9632884). For the
remaining assays, the genotypes of outlying samples were
manually called following examination of the mass spectrum
profiles. Within each iPLEX experiment, samples which had
a genotype call rate of ,85% (iPLEX1) or ,87.5%
(iPLEX2) were discarded. Three additional SNPs were elimi-
nated with Hardy–Weinberg equilibrium statistics in controls
.9 (rs518394, rs1333040, rs2811712).
All SNPs, with the exception of rs12379111, had a genotype
call rate .90% and a difference in genotype call rate between
cases and controls ,2%. Concordance with HapMap geno-
type data was .99.5%.
Statistical analysis
Hardy–Weinberg equilibrium was tested using the genhw
StataTM package (23). Haplotyping and genotype imputation
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was performed using the MACH (version 1.0.10) computer
program (24). MACH implements a Markov chain algorithm
for extended haplotyping of unrelated individuals; the result-
ing haplotype frequency information can then be used to
drive a genotype imputation procedure. Two hundred haplo-
type states (for updating each individual) were examined to
balance the desire to explore the (potentially enormous)
space of possible haplotypes as comprehensively as possible
with finite computer resources. Five hundred rounds of the
Markov sampler were performed; a comparison of results
based on 100 and 500 rounds were similar (data not shown),
suggesting that an acceptable convergence was attained.
MACH reports quality scores to quantify the accuracy of
imputed missing genotypes; imputed genotypes with scores
.0.85 were included in the analysis.
Association analyses were performed using regression
models (logistic and multinomial logistic for categorical out-
comes, linear for continuous quantitative traits). A mixture
of unrelated (some cases and all controls) and related (affected
siblings) individuals were included in the analysis; this famil-
ial clustering was modelled by using a robust sandwich esti-
mation of the variance (25) as implemented in StataTM
version 9.2. Country-of-origin was included as a categorical
main-effect to indirectly model differences in SNP allele fre-
quencies across the populations, a technique which efficiently
absorbs this source of over-dispersion (26). Additive and non-
additive effects were modelled by defining continuous vari-
ables with levels 0, 1 & 2 or 0, 1 & 0, respectively, corre-
sponding to genotypes AA, AB & BB. In the context of
logistic regression, an additive-effects-only model predicting
categorical (disease status) outcomes in terms of logit [i.e.
log(odds ratio)] effects is equivalent to a multiplicative odds
ratio model (i.e. a model of allelic association); inclusion of
non-additive effects was used to model non-multiplicative
associations (i.e. a model of genotype association).
Meta-analysis was performed using fixed-effects (inverse
variance weighting) methods implemented in the metan
StataTMpackage (27).
Biochemical phenotypes
Total plasma cholesterol, HDL cholesterol, triglycerides,
albumin, urate and bilirubin were measured at baseline using
commercial standard clinical chemistry kits (Roche Diagnos-
tics GmbH, Mannheim, Germany) on a Hitachi 917 Roche
automated clinical chemistry analyser in CAD cases. LDL
cholesterol was calculated using the Friedewald formula if tri-
glycerides were 4.5 mmol/L (400 mg/dL). Lp(a) was
measured by a latex-enhanced immunoturbidimetric test
from Immuno (Vienna, Austria). (28). Determinations of
cholesterol, HDL-cholesterol and triglycerides were controlled
by the NHLBI Lipid Standardization Program organized by
the Centers for Disease Control (CDC, Atlanta, GA, USA).
Homocysteine in CAD cases was measured by reverse-phase
high-performance liquid chromatography with a commercial
assay kit (Chromsystems) on an isocratic liquid chromato-
graph (Kontron, Neufahrn, Germany) interfaced with a fluor-
escence detector (model RF-535, Shimadzu, Kyoto, Japan).
Cotinine levels in CAD cases were measured using a serum
cotinine microplate enzyme immunoassay (Cozart Bioscience
Ltd, Abingdon, UK). Plasma fibrinogen concentration in CAD
cases was determined with the Clauss assay (29) using the
Fibrinogen-C kit and calibration plasma from Instrumentation
Laboratory SpA (Milano, Italy), in the ACL 9000 coagulation
analyser (Instrumentation Laboratory). Coefficients of vari-
ation for a normal control plasma for coagulation analysis
from Global Hemostasis Institute (Linko¨ping, Sweden) were
2% (intra-assay) and 7% (inter-assay, n ¼ 106).
For those biochemical phenotypes that are known to be
modified by statins (LDL-cholesterol, HDL-cholesterol and
triglycerides), CAD patients taking this medication were
excluded from the lipid association analysis. The distribution
of the continuous phenotypes was examined by use of quan-
tile–quantile plots and histograms, a few extreme outliers
(which are likely to be due to measurement or data entry
errors) were eliminated. Markedly non-normally distributed
traits were log, reciprocal-square-root or square-root trans-
formed before analysis (and then asymptotic P-values are
reported) or variance–covariance estimates were derived
empirically by bootstrapping (200 replicates). Covariates
(age, sex, BMI, current smoking status and cotinine level (to
assess exposure to passive smoking) were selected on the
basis of prior expectation and exploratory regression analyses
(data not shown) on a trait-by-trait basis.
RT–PCR analysis
Primers were designed using Primer3 (30) in exon 17
(CAGAGCAATTCCAGTGCAAG) and exon 18 (GATTTG-
CAAAAACAGCTG) or exon 18 (AGCTTTCTGCTACAT
GGAGGCTAG) and exon 19 (GGCAAATCACTTTT-
CATCTTTCTGTAT) to give a product size of 176 or
177 bp by reverse transcription PCR. RNA was obtained by
extraction with TRIazol (Invitrogen) from carotid endarterect-
omy and abdominal aortic aneurysm tissue samples and
human cell cultures and lines according to the manufacturer’s
instructions. In the case of human monocyte-derived macro-
phages and human skin fibroblasts, RNA was isolated employ-
ing the RNeasy Mini kit (Qiagen) according to the supplier’s
instructions. Contaminating genomic DNA was removed by
treatment with DNase I (Qiagen). RT–PCR was (performed
on 10–100 ng RNA) using the Quantitect one step RT–PCR
kit (Qiagen, Valencia, CA, USA) using the Corbett Life
Science Rotor-Gene 3000 system or the ABI PRISMw
7900HT Sequence Detection System (Applied Biosystems)
and the QuantiTect SYBRwGreen PCR kit (Qiagen). Products
were size fractionated on a 1% agarose gel.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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